Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma.

ABSTRACT:

Background

Metastatic melanoma is an aggressive skin cancer with a poor prognosis. Current treatment strategies for high-stage melanoma are based around the use of immunotherapy with immune checkpoint inhibitors such as anti-PDL1 or anti-CTLA4 antibodies to stimulate anti-cancer T cell responses, yet a number of patients will relapse and die of disease. Here, we report the first sustained complete remission in a patient with metastatic melanoma who failed two immunotherapy strategies, by targeting tumour arginine metabolism.

Case presentation

A 65-year-old patient with metastatic melanoma who progressed through two immunotherapy strategies with immune checkpoint inhibitor antibodies was enrolled in a phase I study (NCT02285101) and treated with 2 mg/kg intravenously, weekly

SUBMITTER: De Santo C 

PROVIDER: S-EPMC5960181 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature